Compounds > lapatinib
Page last updated: 2024-09-05

lapatinib and at 7519

lapatinib has been researched along with at 7519 in 3 studies

Compound Research Comparison

Studies
(lapatinib)		Trials
(lapatinib)		Recent Studies (post-2010)
(lapatinib)		Studies
(at 7519)		Trials
(at 7519)		Recent Studies (post-2010) (at 7519)
1,9193051,44227024

Protein Interaction Comparison

ProteinTaxonomylapatinib (IC50)at 7519 (IC50)
Cyclin-T1Homo sapiens (human)0.0093
Cyclin-dependent kinase 14Homo sapiens (human)0.0198
Cyclin-dependent kinase 1Homo sapiens (human)0.1729
Cyclin-dependent kinase 4Homo sapiens (human)0.0939
G2/mitotic-specific cyclin-B1Homo sapiens (human)0.1682
Cyclin-A2Homo sapiens (human)0.063
G1/S-specific cyclin-D1Homo sapiens (human)0.1168
G1/S-specific cyclin-E1Homo sapiens (human)0.36
Cyclin-dependent kinase 2Homo sapiens (human)0.0586
G1/S-specific cyclin-D3Homo sapiens (human)0.153
Glycogen synthase kinase-3 betaHomo sapiens (human)0.2
Cyclin-dependent kinase 7Homo sapiens (human)2.4
Cyclin-dependent kinase 9Homo sapiens (human)0.0094
Cyclin-HHomo sapiens (human)2.4
CDK-activating kinase assembly factor MAT1Homo sapiens (human)2.4
Cyclin-A1Homo sapiens (human)0.047
Cyclin-dependent kinase 3Homo sapiens (human)0.36
Cyclin-dependent kinase 6Homo sapiens (human)0.1775
Cyclin-dependent-like kinase 5 Homo sapiens (human)0.1393
Cyclin-dependent kinase 5 activator 1Homo sapiens (human)0.1813
Cyclin-YHomo sapiens (human)0.0198

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1

Other Studies

3 other study(ies) available for lapatinib and at 7519

ArticleYear
Comprehensive analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11

    Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity

2011
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017